Phase 2 Bladder Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older at the time of giving consent
- People who have been diagnosed with cancer (confirmed by lab testing of tissue), or in the case of liver cancer (hepatocellular carcinoma), by imaging scans alone
- People whose cancer type is one of those listed as eligible (see the full list above, which includes cancers such as breast, lung, colorectal, prostate, ovarian, multiple myeloma, melanoma, and others)
- People who are currently receiving one of the specific treatment regimens listed in the trial (such as pembrolizumab, nivolumab, trastuzumab, bevacizumab, and others listed above)
- People whose treatment is either approved by the FDA for their cancer type, or recommended in recognised national cancer guidelines (such as NCCN, ASCO, or ASH)
- People whose treating doctor considers them to have tolerated their current treatment well, with no significant harmful reactions before joining
- People whose treating doctor rates their physical functioning as appropriate for participation (a standard medical scoring scale is used for this)
- People who a social stability screening tool — used as part of standard care — identifies as appropriate for the at-home care programme in this trial
- People whose treating doctor expects them to continue their current eligible treatment for at least 12 weeks from the time of joining the trial
- People who live within the Florida Panhandle and surrounding areas served by the home healthcare and paramedic network used in this study
- People whose home has an existing Wi-Fi connection, or where a mobile Wi-Fi device provided through the programme can establish a reliable connection to the remote care centre at Mayo Clinic
- People who are willing and able to follow the study procedures, in their doctor's judgement
- People willing to follow birth control requirements if they are able to have children (male or female)
- People willing to return to the enrolling medical facility for follow-up visits during the active monitoring phase
- People who are able to complete questionnaires on their own or with help
- People who provide written informed consent
Who may not be able to join:
- People with serious ongoing illnesses or other severe health conditions that, in the investigator's judgement, would make participation inappropriate or affect the safe assessment of their treatment
- People who are currently receiving an experimental (investigational) treatment for their cancer as part of another study
- People who need around-the-clock (24/7) assistance with daily activities and are unable to manage the technology required for the study, unless a caregiver is available and willing to provide consistent support throughout the entire study period
- People who are currently admitted to a hospital as an inpatient (except those enrolled in the Advanced Care at Home programme)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Roxana S. Dronca, MD, Mayo Clinic
Phone: 855-776-0015
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Patient preferences regarding location of cancer treatment delivery; Adverse Events Related to Location of Treatment; Incidence of avoidable acute care visits, emergency room visits, and hospitalizations
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.